The first step in personalized treatments is understanding the genetic and biological characteristics of the tumor. For this purpose, genomic tests, liquid biopsies (ctDNA), and other molecular analysis methods are used.

• Genomic Tests: Identify mutations and targetable biomarkers in the tumor’s genetic structure. For example, mutations such as EGFR, ALK, and KRAS play a critical role in determining the appropriate treatment.

• Liquid Biopsy: Analyzes tumor DNA in the bloodstream and can be used for both diagnosis and treatment monitoring.

Based on this data, a treatment plan suitable for the patient’s tumor biology and overall health status is prepared.

What is the Difference from Traditional Treatments?

Traditional treatments typically aim to apply the same drugs or methods to a group of patients. However, cancer cells are genetically very different from each other, and this can cause some patients not to respond to treatments. Personalized treatment eliminates this problem.

Key differences:

• Targeted Approach: Reduces the possibility of harming healthy cells by targeting only cancer cells.

• Fewer Side Effects: Side effects are less frequent and more predictable compared to traditional treatments.

• Higher Success Rate: The response rate to treatment increases thanks to genetic compatibility.

Why is Knowing the Patient’s History Important?

A patient’s history is as important as genetic analysis in treatment planning. Age, lifestyle, accompanying diseases, previous treatments, and psychological status are factors that directly affect treatment success. Therefore, I evaluate my patients not just as a genetic profile, but as a whole. The success of the treatment is possible by meeting both the physical and psychological needs of the patient.

Can it be Used in Every Stage of Cancer?

Yes, personalized treatments can be applied at every stage of cancer.

• Early Stage: Can be used to shrink the tumor and assist with surgery.

• Advanced Stage: Preferred to slow down or control the growth of cancer.

• Relapsed and Refractory Cancers: Offers an alternative solution for patients who do not respond to traditional treatments.

How Do I Approach It?

In my approach, every patient is unique with their own genetic and biological characteristics. Before starting the treatment process, I conduct a comprehensive evaluation:

• Genetic and Molecular Tests: I identify the genetic mutations found in the patient’s tumor. For example, in a patient with EGFR mutation in lung cancer, I use targeted drugs such as osimertinib.

• Detailed Patient History: The patient’s overall health status, lifestyle, and expectations are included in the treatment process.

• Combined Treatment Approaches: If necessary, I combine immunotherapy and targeted therapies to achieve more effective results.

• Continuous Monitoring: During treatment, I regularly monitor the patient’s response and update the treatment plan if necessary.